Shares of First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT - Get Free Report) fell 1% during mid-day trading on Thursday . The stock traded as low as GBX 1,490.40 ($20.22) and last traded at GBX 1,490.40 ($20.22). 3 shares were traded during trading, a decline of 100% from the average session volume of 8,687 shares. The stock had previously closed at GBX 1,504.70 ($20.42).
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Price Performance
The company has a market cap of £611.38 million and a price-to-earnings ratio of -1,354.91. The business's fifty day moving average price is GBX 1,460.44 and its 200 day moving average price is GBX 1,599.26.
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Company Profile
(
Get Free Report)
Forbidden Technologies plc develops and owns cloud-based video technology in the United Kingdom, North America, and internationally. It offers Forscene, a cloud based video post-production and publishing platform with various applications, such as editing, adding closed caption, graphics, metadata fast, remote viewing, collaboration, and publishing content.
See Also
Before you consider First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation wasn't on the list.
While First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
